Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center
Fabian B. T. Kraus,Elena Sultova,Kathrin Heinrich,Andreas Jung,C. Benedikt Westphalen,Christina V. Tauber,Jörg Kumbrink,Martina Rudelius,Frederick Klauschen,Philipp A. Greif,Alexander König,Anca Chelariu-Raicu,Bastian Czogalla,Alexander Burges,Sven Mahner,Rachel Wuerstlein,Fabian Trillsch
DOI: https://doi.org/10.3390/ijms25042345
IF: 5.6
2024-02-16
International Journal of Molecular Sciences
Abstract:Advances in molecular tumor diagnostics have transformed cancer care. However, it remains unclear whether precision oncology has the same impact and transformative nature across all malignancies. We conducted a retrospective analysis of patients with human papillomavirus (HPV)-related gynecologic malignancies who underwent comprehensive molecular profiling and subsequent discussion at the interdisciplinary Molecular Tumor Board (MTB) of the University Hospital, LMU Munich, between 11/2017 and 06/2022. We identified a total cohort of 31 patients diagnosed with cervical (CC), vaginal or vulvar cancer. Twenty-two patients (fraction: 0.71) harbored at least one mutation. Fifteen patients (0.48) had an actionable mutation and fourteen (0.45) received a recommendation for a targeted treatment within the MTB. One CC patient received a biomarker-guided treatment recommended by the MTB and achieved stable disease on the mTOR inhibitor temsirolimus for eight months. Factors leading to non-adherence to MTB recommendations in other patient cases included informed patient refusal, rapid deterioration, stable disease, or use of alternative targeted but biomarker-agnostic treatments such as antibody–drug conjugates or checkpoint inhibitors. Despite a remarkable rate of actionable mutations in HPV-related gynecologic malignancies at our institution, immediate implementation of biomarker-guided targeted treatment recommendations remained low, and access to targeted treatment options after MTB discussion remained a major challenge.
biochemistry & molecular biology,chemistry, multidisciplinary